000			03269cam a2200325 a 4500
003			EG-GiCUC
008			210623s2021 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2021.Fa.N
100	0		_aFatma Mohamed Ahmed Elsenosy
245	1	2	_aA novel drug design for bioavailability enhancement / _cFatma Mohamed Ahmed Elsenosy ; Supervised Ghada Ahmed Abdelbary , Ahmed Hassan , Ibrahim Elsayed
246	1	5	_aتصميم دوائى جديد لتحفيز الأتاحة الحيوية
260			_aCairo : _bFatma Mohamed Ahmed Elsenosy , _c2021
300			_a94 P . : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aDuloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor. The claimed mechanism of action of DLX is based on the specific inhibition of both serotonin and norepinephrine reuptake, while it weakly inhibits dopamine reuptake and has no significant affinity for histaminergic, dopaminergic, cholinergic or adrenergic receptors. DLX used in major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy and fibromyalgia. DLX is well absorbed after oral administration with 2 {u2013}hour lag time until absorption begins.DLX suffering from limited bioavailability ({uF0BB} 40%) due to extensive hepatic metabolism. This work aims to formulate and evaluate DLX intranasal thermoreversible cubosomal gels to enhance its bioavailability and ensure efficient brain targeting. The nasal route improves drug bioavailability by bypassing first-pass hepatic metabolism and allows direct delivery to the systemic circulation. The nasal route has privilege in brain targeting by direct drug transfer to the brain through neuronal pathway and avoidance of the blood-brain barrier. The in situ nasal gel prolongs formulation residence time and increase penetration rate with drug absorption improvement. Cubo-gels were prepared by three factors, three levels 33 central composite design to formulate 15 formulations with 5 repetitions of the center point formulation (F8). The three independent factors, lipid ratio (glycerol monooleate: glycerol tripalmitate), Pluronic F127 percent and Pluronic F68 percent. The dependant variables were particle size (PS), gelling temperature (GT), entrapment efficiency (EE %) and in-vitro release. The polydispersity index (PDI) and Zeta potential (ZP) were also measured for the prepared formulations. The PS for the prepared formulation ranged from 145.5nm to 515.9 nm, PDI ranged from 0.3 to 1, ZP ranged from 1.6 to 10.6, GT from 32oc to 80 oc, EE% from 93.1% to 99.7% and Q6 % from 20.3% to 64.5%. The cubo-gel with the highest desirability (0.88) was chosen as the optimized formula using Design Expert® software
530			_aIssued also as CD
653		4	_aBioavailability enhancement
653		4	_aDrug design
653		4	_aDuloxetine (DLX)
700	0		_aAhmed Hassan , _eSupervising
700	0		_aGhada Ahmed Abdelbary , _eSupervising
700	0		_aIbrahim Elsayed , _eSupervising
905			_aAmira _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c81367 _d81367